Scynexis entered into an exclusive agreement with GSK for Brexafemme (ibrexafungerp), a U.S. FDA approved antifungal for the treatment of vaginal yeast infections and vulvovaginal candidiasis (VVC). Under the terms of the global license agreement, GSK will pay Scynexis $90 million upfront, plus additional potential milestone-based payments, for a total of $593 million plus royalties. The deal is expected to close by the end of Q2. The upfront payment will result in a cash runway of more th...